Outcome of High-Risk and Refractory AML/MDS Patients Receiving a Flamsa Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)
Marie Y. Detrait(Hôpital Civil de Charleroi), Mauricette Michallet(Université Claude Bernard Lyon 1), Mohamad Mohty(Sorbonne Université), Nathalie Tedone(Hospices Civils de Lyon), Patrice Chevallier(Hotel Dieu Hospital), Stéphane Morisset(Lyon 1 Université), Fiorenza Barraco(Hôpital Lyon Sud), J. Delaunay(Université Paris-Sud), Youcef Chelghoum(Hôpital Edouard Herriot), Xavier Thomas(Hôpital Lyon Sud), Mohamed Sobh(Hospices Civils de Lyon), Franck E. Nicolini(Hôpital Lyon Sud), Sophie Ducastelle(Hôpital Lyon Sud), Hélène Labussière(Hôpital Lyon Sud), Thierry Guillaume(Centre National de la Recherche Scientifique)
Cited by 4
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547